Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2018, Vol. 45 Issue (4): 485-492    DOI: 10.12891/ceog4046.2018
Review | Next articles
The importance of angiogenic and antiangiogenic biomarkers in pathogenesis and early diagnosis of preeclampsia
R. Einikytė1, A. Dapkeviciute1, V. Dzenkeviciute2, 3, *(), S. Kasnauskiene3, V. Sapoka2, 3, D. Ramasauskaite3, 4
1 Faculty of Medicine, Vilnius University, Vilnius, Lithuania
2 Faculty of Medicine, Clinic of internal medicine, oncology and family medicine;Vilnius University, Vilnius, Lithuania
3 Vilnius University Hospital Santariskiu Clinics, Vilnius, Lithuania
4 Faculty of Medicine, clinic of obstetric and gynaecology, Vilnius University, Vilnius, Lithuania
Download:  PDF
Export:  BibTeX | EndNote (RIS)      
Abstract  
The early diagnosis of preeclampsia (PE) remains one of the great medical problems worldwide. PE is a multisystemic disorder and the etiology is still unclear. The equilibrium between anti-angionenic and angiogenic factors is essential in the PE pathogenesis. In this review, the authors highlight the role of key circulating anti-angionenic and antiangiogenic factors as pathogenic biomarkers and as well as early diagnostic biomarkers for PE. They analyzed the main anti-angiogenic factors: soluble FMS–like tyrosine kinase (sFlt-1), soluble endoglin (sEng), and the angiogenic factors – vascular endothelial growth factor (VEGF) and placental growth factor (P1GF). An accurate algorithm for diagnosing PE using only biomarkers is still absent.
Key words:  Preeclampsia      Anti-angiogenic factors      Angiogenic factors      Biomarkers     
Published:  10 August 2018     
*Corresponding Author(s):  V. DŽENKEVIČIŪTĖ     E-mail:  vilma.dzenkeviciute@santa.lt

Cite this article: 

R. Einikytė, A. Dapkeviciute, V. Dzenkeviciute, S. Kasnauskiene, V. Sapoka, D. Ramasauskaite. The importance of angiogenic and antiangiogenic biomarkers in pathogenesis and early diagnosis of preeclampsia. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(4): 485-492.

URL: 

https://ceog.imrpress.com/EN/10.12891/ceog4046.2018     OR     https://ceog.imrpress.com/EN/Y2018/V45/I4/485

[1] H.M. Kim, Y.S. Choo, W.J. Seong. Serum NT-proBNP levels as a marker for cardiopulmonary function in preeclampsia[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 511-515.
[2] H. Yolli, M.E. Demir, R. Yildizhan. Neutrophil gelatinase associated lipocalin-2 (Ngal) levels in preeclampsia[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 519-523.
[3] A.E. Kholeif, M.Y. Khamis, S. Eltabakh, R.S. Swilam, A. Elhabashy, R. EISherif. Prediction of severity of preeclampsia in Egyptian patients: role of neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and C-reactive protein[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(2): 183-188.
[4] J. Yoon Park, S.W. Lee, K.J. Oh, J.-S. Hong. High mean blood pressure during the first trimester is predictive of future preeclampsia development in healthy pregnant women: a cohort study in Korea[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(5): 770-775.
[5] Y.E. Purut, E.E. Buyukbayrak, F. Ercan, A. Orcun, M. Menke, A.Y. Karageyim Karsidag. Do first trimester maternal serum follistatin like 3 levels predict preeclampsia and/or related adverse pregnancy outcomes?[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(2): 195-200.
[6] E. Ertekin, Ö. Tunçyürek, S. Kafkas, Y. Özsunar. Does the placental strain ratio correlate with the umbilical artery Doppler values?[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(2): 227-230.
[7] A. Simsek, S. Uludag, A. Tuten, A. S. Acikgoz, S. Uludag. Maternal and perinatal outcomes in early onset and late onset preeclampsia[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(6): 837-841.
[8] B. Dullaert, S. Schroven, Y. Jacquemyn. The effect of maternal vitamin D status on pregnancy outcome and child health in the first year of life[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(5): 677-681.
[9] P. Bolehovska, D. Driak, M. Halaska, B. Asfaw, J. Novotny, I. Svandova. Disturbed angiogenesis in intrauterine growth restriction-compromised placentas at term[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(5): 707-712.
[10] Jinqi Ma, Hua Yao. Persistent hypertension post-preeclampsia: a tertiary care centre-based study in China[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(5): 741-744.
[11] H. Kobayashi, T. Tsunemi, J. Akasaka, N. Koike, A. Shigemitsu. F. Ito, Y. Yamada, E. Fujii. Preeclampsia as a parental epigenetic disease[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(4): 493-502.
[12] A. Jafari, S. Parchami, S. Reiisi, S. Miraj. Association of plasma homocysteine, folic acid levels, and C677T polymorphism in methylene tetra hydrofolate reductase with risk of preeclampsia: a case-control study in Iranian women[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(3): 367-374.
[13] E. Shim, J.Y. Park, H.J. Seol. Placental expression of retinol-binding protein 4 in patients with preeclampsia[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(1): 98-101.
[14] B.S. Joo, J.B. Son, M.J. Park, J.K. Joo, C.W. Kim, K.S. Lee. Effect of regular exercise on reproductive function of aged female in mouse model[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(6): 839-846.
[15] R. Lukic, M. Djukic, I. Soldatovic, N. Karadzov Orlic, D. Ardalic, G. Dragovic, Z. Mikovic. Prediction of preeclampsia using extreme first-trimester PAPP-A, free βhCG and uterine artery Doppler in resource limited settings[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(6): 851-855.
No Suggested Reading articles found!